KR20230156731A - 뇌암 치료에 이용하기 위한 벨바라페닙 - Google Patents

뇌암 치료에 이용하기 위한 벨바라페닙 Download PDF

Info

Publication number
KR20230156731A
KR20230156731A KR1020237033790A KR20237033790A KR20230156731A KR 20230156731 A KR20230156731 A KR 20230156731A KR 1020237033790 A KR1020237033790 A KR 1020237033790A KR 20237033790 A KR20237033790 A KR 20237033790A KR 20230156731 A KR20230156731 A KR 20230156731A
Authority
KR
South Korea
Prior art keywords
mutation
cancer
nras
melanoma
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033790A
Other languages
English (en)
Korean (ko)
Inventor
조앤 아담케윅츠
마이클 존 돌톤
시바 말레크
피이아 토마스
제니퍼 엥-웡
이빙 얀
영훈 김
영길 안
유연 김
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게, 한미약품 주식회사 filed Critical 제넨테크, 인크.
Publication of KR20230156731A publication Critical patent/KR20230156731A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237033790A 2021-03-09 2022-03-08 뇌암 치료에 이용하기 위한 벨바라페닙 Pending KR20230156731A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163158798P 2021-03-09 2021-03-09
US63/158,798 2021-03-09
PCT/US2022/019273 WO2022192202A1 (en) 2021-03-09 2022-03-08 Belvarafenib for use in treatment of brain cancers

Publications (1)

Publication Number Publication Date
KR20230156731A true KR20230156731A (ko) 2023-11-14

Family

ID=80952247

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033790A Pending KR20230156731A (ko) 2021-03-09 2022-03-08 뇌암 치료에 이용하기 위한 벨바라페닙

Country Status (7)

Country Link
US (1) US20240173329A1 (https=)
EP (1) EP4304592A1 (https=)
JP (1) JP2024509269A (https=)
KR (1) KR20230156731A (https=)
CN (1) CN117940130A (https=)
TW (1) TW202300151A (https=)
WO (1) WO2022192202A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
BR112014015720B1 (pt) 2011-12-30 2020-03-17 Hanmi Pharm. Co., Ltd. Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
EP3624896A4 (en) * 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
IL274969B2 (en) * 2017-11-30 2026-03-01 Hanmi Pharmaceutical Co Ltd Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[2,3-D]pyrimidine-7-carboxamide, and crystalline forms thereof
EP3560516A1 (en) * 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CA3178927A1 (en) * 2020-05-26 2021-12-02 Hanmi Pharm. Co., Ltd. Belvarafenib for use in cancer treatment

Also Published As

Publication number Publication date
US20240173329A1 (en) 2024-05-30
WO2022192202A1 (en) 2022-09-15
CN117940130A (zh) 2024-04-26
JP2024509269A (ja) 2024-02-29
EP4304592A1 (en) 2024-01-17
TW202300151A (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
JP7520189B2 (ja) 組み合わせ療法
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
DK2605764T3 (en) Compositions for the treatment of cancer
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
WO2015112888A1 (en) Apilimod compositions and methods for using same
JP2024537794A (ja) ヘテロ芳香族大環状エーテル化合物を使用して固形腫瘍を治療する方法
WO2017210538A1 (en) Pharmaceutical combinations
US10821114B2 (en) Derivatives of cephalosporin for treating cancer
KR20230156731A (ko) 뇌암 치료에 이용하기 위한 벨바라페닙
HK40108904A (zh) 用於脑癌治疗的贝伐拉非尼
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
KR20230170668A (ko) Fgfr2 및 암 유발 유전자의 동시발생 유전자 변형이 있는 환자의 암 치료
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250307

Comment text: Request for Examination of Application